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Abstract: Despite accumulating preclinical data demonstrating a crucial role of cytotoxic T cell
immunity during viral infections, ongoing efforts on developing COVID-19 vaccines are mostly
focused on antibodies. In this commentary article, we discuss potential benefits of cytotoxic T cells in
providing long-term protection against COVID-19. Further, we propose that gamma-ray irradiation,
which is a previously tested inactivation method, may be utilized to prepare an experimental
COVID-19 vaccine that can provide balanced immunity involving both B and T cells.
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In excess of 100 experimental vaccines against COVID-19 are in development, of which more than
40 are currently being evaluated in clinical trials [1]. Primarily, these experimental vaccines are focused
on induction of virus-neutralizing antibodies using various vaccine technology platforms such as
synthetic spike proteins and viral vectors. This is not surprising, given that historically antibodies have
been used as an immune correlate of vaccine-mediated protection against infectious diseases. However,
given our understanding of SARS-CoV-2, one would predict that CD4+ T cells and CD8+ cytotoxic T
(Tc) cells will play an important role in facilitating recovery and protection against severe COVID-19.
The potential benefit of additional Tc cell-mediated immunity is not only in preventing deaths but also
in minimizing the risk of transmission to others by reducing viral load and thus shedding during the
recovery phase.
The important feature of an effective vaccine is induction of long-lived immunity. A recently
published non-human primate study demonstrated that primary SARS-CoV-2 infection provides
protection against homologous re-infection 4 weeks after the initial exposure, and this protection was
found to be associated with neutralizing antibodies [2]. However, while achieving sterilizing immunity
via induction of neutralizing antibodies appears feasible, growing concerns exist that protective levels
of neutralizing antibodies do not persist. Numerous clinical studies have shown that antigen-specific
antibodies and neutralizing antibodies against SARS, a disease caused by a closely related coronavirus,
can wane rapidly within 1-3 years among survivors of the 2003 SARS epidemic [3,4]. It is noteworthy
that human coronaviruses, although less virulent, have been causing seasonal infections, much like
influenza, which indicates that either viral mutation enables coronaviruses to evade antibodies
and/or antibody-mediated protection is short-lived [5]. Indeed, studies show that reinfection with
seasonal coronaviruses occurs frequently, with protective immunity lasting as little as 80 days [6,7].
Similarly, an early study on SARS-CoV-2 reported that some individuals who apparently recovered
from laboratory-confirmed COVID-19 have tested positive a second time, an indication of potential
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reinfection [8,9]. Furthermore, a recent serological study reported that 40% and 12.9% of asymptomatic
and symptomatic individuals, respectively, became seronegative within 2–3 months after infection [10].
Therefore, unless the vaccine induces immunity more efficiently than the live virus, one would expect
that vaccine-induced antibodies will likewise be short lasting. Achieving sterilizing immunity by
antibody-based vaccines may prove difficult.
Given the above, Tc cell immunity against coronaviruses may present an important aspect of
any successful vaccine as it is thought to be long-lived. Recent studies have detected SARS-CoV-2
reactive T cells that are capable of expressing IFNγ and/or granzyme B in 40~60% of uninfected
individuals [11,12]. Notably, this percentage increased to 80–100% for convalescent COVID-19 patients,
suggesting that (1) unlike antibodies, Tc cells against coronaviruses persist in humans and can be
detected months and/or years after an infection; (2) memory Tc cells are directed against conserved
regions of coronaviruses and therefore are broadly cross-reactive; and (3) specific T cell responses are
associated with recovery from SARS-CoV-2 infection. An implication based on these observations is that
coronaviruses will be less likely to evade Tc cell immunity due to MHC class I polymorphism. Indeed,
a potential benefit of T cell responses was recently demonstrated in two clinical studies that found
an inverse correlation between severe COVID-19 and lower CD4+ and CD8+ T cell blood counts on
admission [13,14]. Thus, there are realistic benefits for considering T cell-based vaccination approaches
against COVID-19. Future studies are needed to determine whether Tc cell immunity influences the
clinical course of SARS-CoV-2 infection and whether the presence of SARS-CoV-2 reactive Tc cells
prior to an infection correlates with the development of less severe COVID-19. It is important to note,
however, that T-cell-based vaccines will unlikely provide sterilizing immunity against SARS-CoV-2
since cytotoxic T cells will engage after an infection of host cells. Therefore, an ideal COVID-19 vaccine
should stimulate both B and T cell immunity to complement each other to provide optimal protection
against severe COVID-19.
Several forms (inactivated, recombinant protein, DNA, RNA, and viral-vector-based) of COVID-19
vaccine candidates are currently being evaluated in clinical trials. Whether these experimental vaccines
are capable of providing protective T cell immunity in humans is currently unknown and should be
investigated. In particular, DNA- and RNA-based vaccines, in theory, should generate MCH-I antigens
in situ in a manner similar to natural viral infection. However, it should be noted that DNA vaccines
have been tested against other infectious diseases in humans and have failed in the past to demonstrate
the induction of strong immune responses [15–17]. As for inactivated and purified viral vaccines,
a substantial amount of data exists in the literature that inactivated antigens are mainly dependent
on the MHC-II pathway and therefore they are not anticipated to mount strong MHC-I-restricted
immune responses [18–20]. Lastly, although several viral vectors are currently approved for human
use, several challenges exist for their application. These include (1) immunodominance of the vector
genes over transgenes; and (2) pre-existing anti-vector immunity due to natural exposure to the virus
or induction of anti-vector immunity upon first use, which would not permit effective use of the same
viral vector in the same patient.
Generally, the generation of Tc cell immunity requires live viral infection, and therefore most
viral inactivation methods eliminate T cell immunogenicity. However, early studies in the 1970s and
80s have identified gamma-irradiation as a superior inactivation method that can better preserve
T cell immunogenicity relative to other inactivation procedures. This favorable characteristic of
gamma-irradiation can be attributed to the high penetrative strength of gamma-rays that cause direct
damage to genetic material without altering structural proteins [21]. Therefore, gamma-irradiated
viruses should be able to infect host cells without producing infectious progeny. Indeed, we have
previously demonstrated that alphaviruses [22] and bunyaviruses [23] can be rendered non-infectious
by gamma-irradiation and yet still possess the capacity to generate cytotoxic T cell responses. We later
applied gamma-irradiation to prepare an experimental influenza vaccine and reported that gamma-ray
irradiated sterile influenza virus preparations promote Tc cell immunity [24–27]. Most importantly,
gamma-ray irradiated influenza virus preparations were highly protective against heterologous
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influenza infections, including H5N1 avian flu, in mice, and this T cell memory was found to be
long-lived [24–26,28]. This experimental protocol of using low dose-rate sterilizing gamma irradiation
of whole viruses for induction of long-lasting Tc cell immunity has been shown to be generally
applicable if the immunodominant Tc cell determinants are located in structural virus proteins [24].
This approach may enable the SARS-CoV-2 spike protein to enter the class I MHC antigen presentation
pathway [11].
The obvious strength of a gamma-ray irradiation approach is that virus replication can be
eliminated while preserving its infectivity and immunogenicity, thus presenting the viral proteins to
the immune system in a natural way, facilitating the induction of both T cell and humoral immunity.
In addition, vaccine manufacturing has been greatly simplified, solely requiring cell culture virus
growth, purification, and low-dose inactivation using a gamma ray source generally readily available
for sterilization procedures of commercial products. Lastly, our previous work has also demonstrated
an antigen dose sparing effect of gamma-irradiated virus in mice [27] (discussed in Furuya [29]). This,
of course, is important during a pandemic when enough vaccine doses are need to be manufactured
with limited production capacity in a short time frame. Therefore, a gamma-ray irradiated virus
vaccine could fulfill the unmet need for a safe, cost-effective, widely distributable COVID-19 vaccine.
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